PMID- 12684682
OWN - NLM
STAT- MEDLINE
DCOM- 20030811
LR  - 20211203
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 22
IP  - 5
DP  - 2003 May
TI  - Elimination of CD4+ T cells may overcome suppression of anti-HER2 immune 
      responses in tumor-bearing hosts.
PG  - 1135-9
AB  - In this study, we analyzed specific anti-tumor immune responses in tumor-bearing 
      hosts by measuring HER2-specific CD8+ T cell responses. No measurable 
      HER2-derived peptide (HER2p63)-specific CD8+ T cells were present in the spleens 
      of mice in the early to late phase of tumor-bearing. Vaccination with HER2 
      protein and cholesteryl group-bearing pullulan (CHP-HER2 complex) induced 
      HER2-specific CD8+ T cells, but their numbers continuously declined as tumors 
      continued growing. Removal of CD4+ T cells by anti-CD4 monoclonal antibody in the 
      early tumor-bearing stage resulted in tumor regression. The combination of 
      CHP-HER2 complex vaccination and depletion of CD4+ T cells enhanced and restored 
      HER2-specific CD8+ T cells in the late stage of tumor-bearing, and also 
      suppressed tumor growth. These results indicate the importance of manipulation of 
      CD4+ T cells in developing effective immunotherapies as cancer vaccines.
FAU - Ishihara, Mikiya
AU  - Ishihara M
AD  - Second Department of Internal Medicine, Mie University School of Medicine, Tsu 
      514-8507, Japan.
FAU - Tawara, Isao
AU  - Tawara I
FAU - Wang, Lijie
AU  - Wang L
FAU - Takahashi, Yoshiyuki
AU  - Takahashi Y
FAU - Shiku, Hiroshi
AU  - Shiku H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (CD4 Antigens)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - CD4 Antigens/immunology
MH  - CD4-Positive T-Lymphocytes/*immunology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Female
MH  - Fibrosarcoma/*immunology
MH  - Immunosuppression Therapy
MH  - Immunotherapy
MH  - *Lymphocyte Depletion
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Receptor, ErbB-2/*immunology
MH  - Spleen/immunology
EDAT- 2003/04/10 05:00
MHDA- 2003/08/12 05:00
CRDT- 2003/04/10 05:00
PHST- 2003/04/10 05:00 [pubmed]
PHST- 2003/08/12 05:00 [medline]
PHST- 2003/04/10 05:00 [entrez]
PST - ppublish
SO  - Int J Oncol. 2003 May;22(5):1135-9.